Based in Santa Ana, CA, NKGen Biotech was established in 2017 and is focused on natural killer cell therapies for the treatment of patients in areas such as neurodegenerative disease, such as Alzheimer's and Parkinson's, and oncology.
The announcement did not mention potential deal terms or an estimated valuation for the combined company, if a merger were to be completed.
Graf IV raised nearly $172 million in a May 2021 IPO. Graf II and III withdrew planned IPOs in April 2022. Read more.
Source: Graf Acquisition IV and NKGen Biotech Sign LOI for a Business Combination